Axcella Health Inc.
| NASDAQ: AXLA | Healthcare / Biotechnology / USA |
| 10.35 | +0.7500 | +7.81% | Vol 1.00M | 1Y Perf 448.57% |
| Sep 22nd, 2023 16:00 DELAYED |
| BID | 10.02 | ASK | 10.50 | ||
| Open | 9.41 | Previous Close | 9.60 | ||
| Pre-Market | - | After-Market | 10.06 | ||
| - - | -0.29 -2.77% |
| Target Price | 8.00 | Analyst Rating | Moderate Buy 2.00 | |
| Potential % | -22.71 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/60/14 | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/99/51 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/99/45 | Income Ranking | — - | |
| Price Range Ratio 52W % | 15.79 | Earnings Rating | Buy | |
| Market Cap | 30.51M | Earnings Date | 7th Nov 2023 | |
| Alpha | -0.06 | Standard Deviation | 0.27 | |
| Beta | 1.29 |
Today's Price Range 9.2613.33 | 52W Range 2.5951.75 |
Summary:
Buy
| Technical Indicators: | Buy |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 1 558.92% | ||
| 1 Month | 7 052.73% | ||
| 3 Months | 4 016.95% | ||
| 6 Months | 2 252.27% | ||
| 1 Year | 448.57% | ||
| 3 Years | 141.26% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 166.13 | |||
ROE last 12 Months | -543.23 | |||
ROA (5Y Avg) | -44.27 | |||
ROA last 12 Months | -152.75 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -159.19 | |||
Return on invested Capital Q | -59.71 | |||
Return on invested Capital Y | -31.96 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.20 | ||||
| 8.74 | ||||
| - | ||||
| - | ||||
| -0.50 | ||||
| -1.46 | ||||
| -3.27 | ||||
| -0.10 | ||||
| 26.88M | ||||
| Forward PE | -3.11 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.10 | ||||
| 1.20 | ||||
| 0.71 | ||||
| 3.02 | ||||
| -24.40 | ||||
| Leverage Ratio | 4.70 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -1.25 | -1.25 | 0.00 |
| Q01 2023 | -5.00 | -1.25 | 75.00 |
| Q04 2022 | -6.25 | -7.75 | -24.00 |
| Q03 2022 | -9.25 | -8.50 | 8.11 |
| Q02 2022 | -9.00 | -10.00 | -11.11 |
| Q01 2022 | -0.38 | -0.46 | -21.05 |
| Q04 2021 | -0.43 | -0.46 | -6.98 |
| Q03 2021 | -0.45 | -0.41 | 8.89 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -0.05 | 0.00 | - |
| 12/2023 QR | -0.05 | 0.00 | - |
| 12/2023 FY | -0.20 | 59.18 | Positive |
| 12/2024 FY | -0.20 | 85.19 | Positive |
| Next Report Date | 7th Nov 2023 |
| Estimated EPS Next Report | -1.25 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 1.00M |
| Shares Outstanding | 2.95K |
| Shares Float | 26.67M |
| Trades Count | 10.31K |
| Dollar Volume | 11.07M |
| Avg. Volume | 27.06M |
| Avg. Weekly Volume | 7.31M |
| Avg. Monthly Volume | 54.85M |
| Avg. Quarterly Volume | 19.02M |
Axcella Health Inc. (NASDAQ: AXLA) stock closed at 10.35 per share at the end of the most recent trading day (a 7.81% change compared to the prior day closing price) with a volume of 1.00M shares and market capitalization of 30.50M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 66 people. Axcella Health Inc. CEO is William R. Hinshaw.
The one-year performance of Axcella Health Inc. stock is 448.57%, while year-to-date (YTD) performance is 3060.31%. AXLA stock has a five-year performance of %. Its 52-week range is between 2.5875 and 51.75, which gives AXLA stock a 52-week price range ratio of 15.79%
Axcella Health Inc. currently has a PE ratio of -0.20, a price-to-book (PB) ratio of 8.74, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -152.75%, a ROC of -159.19% and a ROE of -543.23%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Axcella Health Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-1.25 for the next earnings report. Axcella Health Inc.’s next earnings report date is 07th Nov 2023.
The consensus rating of Wall Street analysts for Axcella Health Inc. is Moderate Buy (2), with a target price of $8, which is -22.71% compared to the current price. The earnings rating for Axcella Health Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Axcella Health Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Axcella Health Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 17.25, ATR14 : 1.62, CCI20 : 167.29, Chaikin Money Flow : 0.30, MACD : 2.29, Money Flow Index : 84.79, ROC : 2 406.05, RSI : 78.68, STOCH (14,3) : 69.44, STOCH RSI : 0.63, UO : 60.96, Williams %R : -30.56), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Axcella Health Inc. in the last 12-months were: Fehlner Paul (Sell at a value of $3 446), Koziel Margaret (Sold 679 shares of value $394 ), Paul Fehlner (Sell at a value of $3 447), William R. Hinshaw (Sold 16 000 shares of value $25 027 )
Axcella Health Inc.
Axcella Health Inc a biotechnology company involved in the research and development of novel multifactorial interventions to support health and address dysregulated metabolism. Its AXA candidates are generated from its proprietary, human-focused AXA Development Platform and harness the power of endogenous metabolic modulators, or EMMs. The company's pipeline comprises five programs focused on the metabolic functions of the liver, muscle, and blood.
CEO: William R. Hinshaw
Telephone: +1 857 320-2200
Address: 840 Memorial Drive, Cambridge 02139, MA, US
Number of employees: 66
